OPTION: IV Tenecteplase Boosts Outcomes Late After Non-LVO Stroke

Why It Matters

Extending the thrombolysis window offers a therapeutic option for a large subset of ischemic stroke patients lacking endovascular access, potentially reshaping acute stroke protocols.

Key Takeaways

• Tenecteplase improves 90‑day functional outcome in non‑LVO strokes
• Benefit observed when administered 4.5‑24 hours after onset
• Symptomatic intracranial hemorrhage risk rises modestly with tenecteplase
• Trial limited to Asian cohort; broader validation needed
• CT perfusion selection critical for late‑window thrombolysis

Pulse Analysis

Late‑window thrombolysis has long been constrained to the 4.5‑hour window, primarily for large‑vessel occlusions amenable to mechanical thrombectomy. Non‑LVO strokes, which account for over half of acute ischemic events, have relied on early‑time‑frame IV alteplase despite limited evidence beyond the conventional window. Tenecteplase, a genetically engineered variant of tissue‑type plasminogen activator, offers a longer half‑life and higher fibrin specificity, making it an attractive candidate for extended‑window use. The OPTION trial leverages these pharmacologic advantages, pairing them with advanced CT perfusion imaging to identify salvageable penumbra in patients who would otherwise receive only antiplatelet therapy.

The trial’s primary endpoint—an excellent functional outcome (mRS 0‑1) at 90 days—favored tenecteplase by a relative 32% increase, a statistically robust signal given the 566‑patient sample. Early reperfusion metrics and 24‑hour clinical response also trended positively, suggesting that the drug may achieve meaningful recanalization even without endovascular assistance. However, the rise in symptomatic intracranial hemorrhage, though numerically small, underscores the need for meticulous imaging selection, particularly avoiding patients with extensive non‑contrast CT hypodensity. Mortality and systemic bleeding remained comparable, indicating that the net clinical benefit may outweigh the hemorrhagic risk in carefully screened cohorts.

Looking ahead, the Asian‑centric enrollment limits generalizability, prompting calls for multinational phase III studies that encompass diverse ethnic and comorbidity profiles. Should broader data confirm efficacy and safety, regulatory bodies could expand tenecteplase labeling to include late‑window non‑LVO strokes, prompting hospitals to revise stroke pathways and invest in perfusion imaging capabilities. For Genentech, such an indication would deepen market penetration beyond the current LVO niche, potentially driving significant revenue growth as clinicians adopt tenecteplase as a standard late‑window therapy.